Asthma Classification and Treatment
Core Classification Framework
- The Global Initiative for Asthma (GINA) classifies asthma into three control levels: controlled, partly controlled, and uncontrolled, based on symptom burden and future risk, with treatment organized into 5 stepwise treatment tracks, as recommended by the American Thoracic Society 1
- GINA evaluates two distinct domains: symptom control assessment and future risk assessment, including exacerbation history, risk factors for fixed airflow limitation, and risk factors for medication side effects, as outlined by the American College of Chest Physicians 1
Symptom Control Assessment
- The classification evaluates current impairment using specific criteria, including activity limitation due to asthma, as reported by the American Academy of Family Physicians 3
- Lung function is assessed using PEF or FEV₁ measurements, as recommended by the American College of Physicians 2
Future Risk Assessment
- Risk evaluation includes exacerbation history, particularly those requiring oral corticosteroids, as noted by the American Academy of Family Physicians 3
- Risk factors for fixed airflow limitation include lack of ICS treatment, tobacco smoke exposure, and chronic mucus hypersecretion, as identified by the American Thoracic Society 1
Three-Level Control Classification
- Patients are categorized into one of three control levels: controlled asthma, partly controlled asthma, and uncontrolled asthma, based on control parameters, as defined by the American College of Allergy, Asthma, and Immunology 4
Five-Step Treatment Framework
- GINA organizes treatment into 5 steps of increasing intensity, with two distinct treatment tracks: Track 1 (Preferred) uses low-dose ICS-formoterol as reliever at all steps, and Track 2 (Alternative) uses as-needed SABA across all steps, as outlined by the American College of Chest Physicians 2
- Step 5 additions for severe asthma include long-acting muscarinic antagonists, azithromycin, and phenotype-specific biologic therapies, as recommended by the American Thoracic Society 4
Severity Classification
- When assessing untreated patients to determine initial therapy, GINA recognizes four severity categories: intermittent, persistent-mild, persistent-moderate, and persistent-severe, as classified by the American Academy of Family Physicians 3
- Severity classification is emphasized only for initiating therapy, while control assessment is emphasized for monitoring and adjusting therapy, as noted by the American College of Physicians 5
Key Operational Principles
- Treatment adjustment is bidirectional, with step up when asthma is uncontrolled or partly controlled, and step down when asthma has been well-controlled for ≥3 months, to find the lowest effective dose, as recommended by the American College of Allergy, Asthma, and Immunology 4
- GINA functions as a strategy rather than rigid protocol, requiring adaptation to local healthcare systems and medication availability, as outlined by the American Thoracic Society 2
Pediatric Modifications
- For children aged 6-11 years, GINA 2021 added new treatment options at Steps 3-4, with adjusted control criteria, as recommended by the American Academy of Pediatrics 4
- For children aged 0-2 years, diagnosis relies on symptoms rather than objective testing, as bronchodilator response is variable, as noted by the American Academy of Family Physicians 4